These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 38310905)
1. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Bertran M; D'Aeth JC; Abdullahi F; Eletu S; Andrews NJ; Ramsay ME; Litt DJ; Ladhani SN Lancet Infect Dis; 2024 May; 24(5):546-556. PubMed ID: 38310905 [TBL] [Abstract][Full Text] [Related]
2. Characteristics of children with invasive pneumococcal disease eligible for the 1+1 compared with the 2+1 PCV13 infant immunisation schedule in England: a prospective national observational surveillance study. Abdullahi F; Bertran M; D'Aeth JC; Eletu S; Chan YW; Andrews NJ; Litt DJ; Ramsay ME; Ladhani SN Lancet Child Adolesc Health; 2024 Nov; 8(11):788-797. PubMed ID: 39332425 [TBL] [Abstract][Full Text] [Related]
3. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014. Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682 [TBL] [Abstract][Full Text] [Related]
4. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458 [TBL] [Abstract][Full Text] [Related]
5. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018. Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872 [TBL] [Abstract][Full Text] [Related]
7. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012. Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798 [TBL] [Abstract][Full Text] [Related]
8. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec. De Wals P; Lefebvre B; Deceuninck G; Longtin J Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962 [TBL] [Abstract][Full Text] [Related]
9. Invasive Pneumococcal Disease in UK Children <1 Year of Age in the Post-13-Valent Pneumococcal Conjugate Vaccine Era: What Are the Risks Now? Kent A; Makwana A; Sheppard CL; Collins S; Fry NK; Heath PT; Ramsay M; Ladhani SN Clin Infect Dis; 2019 Jun; 69(1):84-90. PubMed ID: 30281069 [TBL] [Abstract][Full Text] [Related]
10. Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005-19: a cohort observational study. von Gottberg A; Kleynhans J; de Gouveia L; Tempia S; Meiring S; Quan V; du Plessis M; von Mollendorf C; Crowther-Gibson P; Avenant T; du Plessis N; Kularatne R; Chibabhai V; Madhi SA; Klugman KP; Whitney CG; Cohen C; Lancet Glob Health; 2024 Sep; 12(9):e1470-e1484. PubMed ID: 39151982 [TBL] [Abstract][Full Text] [Related]
11. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lo SW; Gladstone RA; van Tonder AJ; Lees JA; du Plessis M; Benisty R; Givon-Lavi N; Hawkins PA; Cornick JE; Kwambana-Adams B; Law PY; Ho PL; Antonio M; Everett DB; Dagan R; von Gottberg A; Klugman KP; McGee L; Breiman RF; Bentley SD; Lancet Infect Dis; 2019 Jul; 19(7):759-769. PubMed ID: 31196809 [TBL] [Abstract][Full Text] [Related]
12. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes. Amin-Chowdhury Z; Groves N; Sheppard CL; Litt D; Fry NK; Andrews N; Ladhani SN Vaccine; 2021 Apr; 39(14):1997-2004. PubMed ID: 33715901 [TBL] [Abstract][Full Text] [Related]
13. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Ladhani SN; Collins S; Djennad A; Sheppard CL; Borrow R; Fry NK; Andrews NJ; Miller E; Ramsay ME Lancet Infect Dis; 2018 Apr; 18(4):441-451. PubMed ID: 29395999 [TBL] [Abstract][Full Text] [Related]
14. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014. Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553 [TBL] [Abstract][Full Text] [Related]
15. Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13. Redin A; Ciruela P; de Sevilla MF; Gomez-Bertomeu F; Gonzalez-Peris S; Benitez MA; Trujillo G; Diaz A; Jou E; Izquierdo C; Perez-Moreno MO; Moraga-Llop F; Olsina M; Vinado B; Sanfeliu E; Garcia A; Gonzalez-di Lauro S; Garcia-Garcia JJ; Dominguez A; Sa-Leao R; Muñoz-Almagro C; Microbiol Spectr; 2021 Dec; 9(3):e0115021. PubMed ID: 34878302 [TBL] [Abstract][Full Text] [Related]
16. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ; Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of Invasive Pneumococcal Disease Caused by Emerging Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in England: A Prospective Observational Cohort Study, 2014-2018. Amin-Chowdhury Z; Collins S; Sheppard C; Litt D; Fry NK; Andrews N; Ladhani SN Clin Infect Dis; 2020 Nov; 71(8):e235-e243. PubMed ID: 31955196 [TBL] [Abstract][Full Text] [Related]
18. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. Moore CE; Paul J; Foster D; Mahar SA; Griffiths D; Knox K; Peto TE; Walker AS; Crook DW; J Infect Dis; 2014 Oct; 210(7):1001-11. PubMed ID: 24719477 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study. Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263 [TBL] [Abstract][Full Text] [Related]
20. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]